Abstract: A ?-crystalline form of ivabradine hydrochloride of formula (I): characterised by its powder X-ray diffraction data. Medicinal products containing the same which are useful as bradycardics.

Abstract: A ?d-Crystalline form of ivabradine hydrochloride of formula (I): characterised by its powder X-ray diffraction data. Medicinal products containing the same which are useful as bradycardics.

Abstract: Process for the synthesis of ivabradine of formula (I): addition salts thereof with a pharmaceutically acceptable acid and hydrates thereof. ? crystalline form of ivabradine hydrochloride. Medicinal products containing ? crystalline form of ivabradine hydrochloride, which are useful as bradycardics.

Abstract: A ?-Crystalline form of ivabradine hydrochloride of formula (I): characterised by its powder X-ray diffraction data. Medicinal products containing the same which are useful as bradycardics.

Abstract: ?-crystalline form of the compound of formula (I): characterized by its powder X-ray diffraction diagram. Medicinal products containing the same which are useful as inhibitors of angiotensin I converting enzyme.

Abstract: The invention concerns a non-therapeutic treatment of the hair and/or the scalp for men and women, wherein it consists in locally applying at the surface of the scalp a complex nutritional base in aqueous medium, comprising at least one fraction of amino acids, one fraction of water soluble vitamins, one inorganic fraction, including trace elements and metal salts but excluding any cell growth factor and/or any untraceable biological extract of animal or cellular origin.

Abstract: Alpha crystalline form of strontium ranelate of formula (I): characterised by its powder X-ray diffraction diagram and by a water content of from 22 to 24%. Medicinal products containing the same which are useful in the treatment of osteoporosis and arthrosis.

Abstract: Compounds of formula (I): wherein: RCy represents an unsubstituted or substituted cycloalkyl group or cycloalkylalkyl group, R1, R2, R3 and R4, which may be the same or different, each represent a hydrogen or halogen atom or a nitro group; a cyano group; a hydroxy group; an alkoxy group; an alkyl group; an unsubstituted or substituted amino group; a carboxy group; an alkoxycarbonyl group; an aryloxycarbonyl group; an unsubstituted or substituted aminocarbonyl group. Medicinal products containing the same which are useful in treating or preventing conditions treatable by an AMPA receptor modulator.

Abstract: A compound selected from those of formula (I): wherein: B1, B2 represent carbon or nitrogen, X, Y, X1 and Y1 represent a group selected from hydrogen, halogen, hydroxy, alkoxy, nitro, cyano, trihaloalkyl and NRaRb wherein Ra and Rb are as defined in the description, R1 represents hydrogen or alkyl, R2 represents a group selected from hydrogen, alkyl, —OR?a, —NR?aR?b, —O-Ta-OR?a, —NR?a-Ta-NR?aR?b, NR?a—C(O)-TaH, —O—C(O)-TaH, —O-Ta-NRa?Rb?, —NR?a-Ta-OR?a, —NR?a-Ta-CO2R?a and —NR?a—C(O)-Ta-NR?aR?b wherein R?a, R?b, R?a and Ta are as defined in the description, R3, R4 represent hydrogen or alkyl, A represents a group of formula —CH(R5)—CH(R6)—, —CH?C(R7)—, —C(R7)?CH—, —C(O)—CH(R8)— or —CH(R8)—C(O)— wherein R5, R6, R7 and R8 are as defined in the description, its isomers, N-oxides, and addition salts thereof with a pharmaceutically acceptable acid or base, and medicinal products containing the same which are useful in the treatment of cancer.

Abstract: The present invention relates to a process for the preparation of mycophenolate mofetil (MMF) in which an ester of mycophenolic acid (MPA) with a low-molecular-weight aliphatic alcohol is transesterified with N-(2-hydroxyethyl)morpholine in the presence of Candida antarctica lipase, and in which the MPA esterification reaction is carried out in the presence of Candida antarctica lipase using the corresponding alcohol as the solvent.

Abstract: Crystalline form IV of the compound of formula (I): characterised by its powder X-ray diffraction diagram. Medicinal products containing the same which are useful in the treatment of melatoninergic disorders.

Abstract: Crystalline form III of the compound of formula (I): characterized by its powder X-ray diffraction diagram. Medicinal products containing the same which are useful in the treatment of melatoninergic disorders.

Abstract: Pupillometric apparatus for assessing pupillary near reflex in a subject incorporates a visible fixation point which is moveable between near and far positions and which is viewable through an eyepiece via an accomodation lens positioned between the eyepiece and the near position. The focal length of the accomodation lens exceeds the distance of the lens from both the near and far positions of the fixation point, so that the subject always observes virtual images in respect of the fixation point. In this way the distance between observed virtual positions of the fixation point at its near and far positions exceeds the actual distance between these positions. Binocular pupillometric apparatus in which images of the left and right pupils of a subject are rapidly and alternately transmitted to the same part of a single image sensor and signal data so obtained are processed to generate separated image data representative of the dimensions of the left and right pupils is also disclosed.

Abstract: Association comprising agomelatine, or N-[2-(7-methoxy-1-naphthyl)ethyl]acetamide, in association with a noradrenaline reuptake inhibitor agent. Medicinal products containing the same which are useful in treating conditions associated with mood disorders.

Abstract: The present invention relates to a new combination of an antithrombotic and aspirin and to pharmaceutical compositions comprising them.

Abstract: A compound selected from those of formula (I): wherein: R1, R2, R3 and R4, which may be the same or different, each represent an atom or group selected from hydrogen, halogen, alkyl, alkoxy, phenyl and cyano, X represents a bond, an oxygen atom or a group selected from —(CH2)m—, —OCH2— and —NR5—, wherein m represents 1 or 2, and R5 is as defined in the description, Y represents an oxygen atom or a group selected from NR7 and CHR8, wherein R7 and R8 are as defined in the description, Z represents a nitrogen atom or a CH group, n represents 1 or 2, Ak represents an alkylene chain, Ar represents an aryl or heteroaryl group, its optical isomers, and addition salts thereof with a pharmaceutically acceptable acid. Medical products containing the same which are useful in the treatment of conditions requiring a serotonin reuptake inhibitor and/or NK1 antagonist.

Abstract: The invention relates to tetrahydroquinolinone derivatives as well as their pharmaceutically acceptable salts. The invention further relates to a process for the preparation of such compounds. The compounds of the invention are group I mGluR antagonists and are therefore useful for the control and prevention of acute and/or chronic neurological disorders.

Abstract: In a process, a polymer is crosslinked and then reversibly bound to a template that is dissolved or suspended in a solvent. The polymer thereby acquires a conformation adapted to the template such that an interaction enthalpy between the template and the polymer is increased by more than 0.1 kcal/mole. The template can be a chemical compound or a biological structure.

Abstract: A compound selected from those of formula (I): wherein m and n, which may be identical or different, each represent an integer from 0 to 2 inclusive, with the sum of the two integers being from 2 to 3 inclusive, p and q, which may be identical or different, each represent an integer from 0 to 2 inclusive, Alk represents an alkylene, alkenylene or alkynylene chain, X represents an oxygen atom, a sulphur atom or an —N(R)— group wherein R represents a hydrogen atom or an alkyl group, Y, Y? and W are as defined in the description, its enantiomers, diastereoisomers, and addition salts thereof with one or more pharmaceutically acceptable acid or base. Medicinal products containing the same which are useful for treating conditions associated with central histaminergic systems.

Abstract: The invention relates to ethynyl-substituted tetrahydroquinolinone derivatives as well as their pharmaceutically acceptable salts. The invention further relates to a process for the preparation of such compounds. The compounds of the invention are group I mGluR modulators and are therefore useful for the control and prevention of acute and/or chronic neurological disorders.